Recombinant monoclonal antibody specially binds to low density lipoprotein (LDL). This mouse anti-LDL antibody (1H11) can be potencially used in the development of vaccines against West Nile Virus.
Figure 1 Anti-OxLDL monoclonal antibodies 1H11 distinguish between human OxLDL and native LDL.
Data are expressed as mean optical density ± standard error oftriplicates.
Boyd, H. C., Gown, A. M., Wolfbauer, G., & Chait, A. (1989). Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. The American journal of pathology, 135(5), 815.
Figure 2 Western blot of human native LDL and OxLDL with antibodies to LDL and to OxLDL.
Prestained molecular weight markers, with molecular weights in kilodaltons at left.
Boyd, H. C., Gown, A. M., Wolfbauer, G., & Chait, A. (1989). Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. The American journal of pathology, 135(5), 815.
Figure 3 Immunofluorescent detection of LDL in atherosclerotic lesions.
Original magnification X215.
Boyd, H. C., Gown, A. M., Wolfbauer, G., & Chait, A. (1989). Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. The American journal of pathology, 135(5), 815.
Figure 4 Demonstration of neoepitope recognition by mAbs by immunohistochemistry.
Scale bars indicate 50 μm.
Torzewski, M., Klouche, M., Hock, J., Meßner, M., Dorweiler, B., Torzewski, J., ... & Bhakdi, S. (1998). Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arteriosclerosis, thrombosis, and vascular biology, 18(3), 369-378.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-615 | Recombinant Anti-LDL Antibody | ELISA, WB, FC, FuncS | IgG |
HPAB-1067WJ | Recombinant Human Anti-LDL Antibody (IEIA8) | ELISA | Human IgG |
HPAB-1068WJ | Recombinant Human Anti-LDL Antibody (IEI-E3) | ELISA | Human IgG |
FAMAB-0056JF | Human Anti-LDL Recombinant Antibody (clone IK17) | WB, ELISA, IHC, Inhib | Human IgG |
FAMAB-0186JF | Mouse Anti-LDL Recombinant Antibody (clone 4E4) | WB, ELISA, IHC, IF | Mouse IgG |
There are currently no Customer reviews or questions for FAMAB-0185JF. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.